Exact Mass: 512.067

Exact Mass Matches: 512.067

Found 31 metabolites which its exact mass value is equals to given mass value 512.067, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

{2-[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-6-yl]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl}oxidanesulfonic acid

{2-[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-6-yl]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl}oxidanesulfonic acid

C21H20O13S (512.0625)


   

{2-[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-8-yl]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl}oxidanesulfonic acid

{2-[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-8-yl]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl}oxidanesulfonic acid

C21H20O13S (512.0625)


   

Vitexin 7-O-sulfate

Vitexin 7-O-sulfate

C21H20O13S (512.0625)


   

Isovitexin 7-O-sulfate

5,7,4-Trihydroxyflavone 6-C-glucoside 7-O-sulfate

C21H20O13S (512.0625)


   

3,5,7-Trihydroxyflavone 3-glucoside-8-sulfate

3- (beta-D-Glucopyranosyloxy) -5,7-dihydroxy-4-oxo-2-phenyl-4H-1-benzopyran-8-sulfonic acid

C21H20O13S (512.0625)


   

Galangin 3-O-beta-D-glucoside-8-sulfonate

(-)-Galangin 3-O-beta-D-glucoside-8-sulfonate

C21H20O13S (512.0625)


   

Sulfemodin-8-O-??-D-glucoside

Sulfemodin-8-O-??-D-glucoside

C21H20O13S (512.0625)


   

apigenin 7-beta-D-glucopyranosyl-2-sulfate|thalassiolin C

apigenin 7-beta-D-glucopyranosyl-2-sulfate|thalassiolin C

C21H20O13S (512.0625)


   

6-sulfooxy-chrysin 7-glucopyranoside

6-sulfooxy-chrysin 7-glucopyranoside

C21H20O13S (512.0625)


   

O鈥樎?Sulfate-Afzelin

O鈥樎?Sulfate-Afzelin

C21H20O13S (512.0625)


   

7-(3,5-dihydroxyphenoxy)-3-(2,4,6-trihydroxyphenoxy)dibenzo-p-dioxin-1,2,6,8-tetrol

7-(3,5-dihydroxyphenoxy)-3-(2,4,6-trihydroxyphenoxy)dibenzo-p-dioxin-1,2,6,8-tetrol

C24H16O13 (512.0591)


   

alpha-Oxo-2,4,6-trihydroxy-3-[2-(3,4-dihydroxyphenyl)-4-oxo-5,7-dihydroxy-2,3-epoxy-3,4-dihydro-2H-1-benzopyran-3-yl]benzeneacetic acid methyl ester

alpha-Oxo-2,4,6-trihydroxy-3-[2-(3,4-dihydroxyphenyl)-4-oxo-5,7-dihydroxy-2,3-epoxy-3,4-dihydro-2H-1-benzopyran-3-yl]benzeneacetic acid methyl ester

C24H16O13 (512.0591)


   
   

2-amino-6-(4-chlorophenyl)sulfanyl-4-[1-[(2R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,4-dioxopyrimidin-5-yl]pyridine-3,5-dicarbonitrile

2-amino-6-(4-chlorophenyl)sulfanyl-4-[1-[(2R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,4-dioxopyrimidin-5-yl]pyridine-3,5-dicarbonitrile

C22H17ClN6O5S (512.067)


   

dTDP-4-dehydro-2,3,6-trideoxy-alpha-D-hexopyranose

dTDP-4-dehydro-2,3,6-trideoxy-alpha-D-hexopyranose

C16H22N2O13P2-2 (512.0597)


   

5-O-{[(1S)-1-carboxylatoethoxy]phosphinato}-1-deoxy-1-(8-hydroxy-2,4-dioxo-2H-pyrimido[4,5-b]quinolin-3-id-10(4H)-yl)-D-ribitol

5-O-{[(1S)-1-carboxylatoethoxy]phosphinato}-1-deoxy-1-(8-hydroxy-2,4-dioxo-2H-pyrimido[4,5-b]quinolin-3-id-10(4H)-yl)-D-ribitol

C19H19N3O12P-3 (512.0706)


   

N-[(6-methoxy-2-oxo-1H-quinolin-3-yl)methyl]-5-methyl-N-(thiophen-2-ylmethyl)-2,1,3-benzothiadiazole-4-sulfonamide

N-[(6-methoxy-2-oxo-1H-quinolin-3-yl)methyl]-5-methyl-N-(thiophen-2-ylmethyl)-2,1,3-benzothiadiazole-4-sulfonamide

C23H20N4O4S3 (512.0647)


   

ustilaginoidin A dianion

ustilaginoidin A dianion

C28H16O10-2 (512.0743)


   

ustilaginoidin A(2-)

ustilaginoidin A(2-)

C28H16O10 (512.0743)


A phenolate anion that is the conjugate base of ustilaginoidin A, obtained by deprotonation of the two hydroxy groups at positions 5 and 5. It is the major microspecies at pH 7.3.

   

dTDP-4-dehydro-2,3,6-trideoxy-alpha-D-glucose(2-)

dTDP-4-dehydro-2,3,6-trideoxy-alpha-D-glucose(2-)

C16H22N2O13P2 (512.0597)


A nucleotide-sugar oxoanion arising from deprotonation of the diphosphate OH groups of dTDP-4-dehydro-2,3,6-trideoxy-alpha-D-glucose; major species at pH 7.3.

   

GSK-25

GSK-25

C24H16Cl2F2N6O (512.0731)


GSK-25 is a potent, selective and orally bioavailable ROCK1 inhibitor (IC50=7 nM). GSK-25 maintains good selectivity against a panel of 31 kinases (>100 fold), as well as RSK1 and p70S6K (RSK1: IC50=398 nM, p70S6K: IC50=1 μM). GSK-25 inhibits P450 profile (IC50s of 2.5, 5.2, 2.5 μM for CYP2C9, CYP2D6, CYP3A4, respectively)[1].

   

(1s,2s,3r,11r,14s)-2-hydroxy-14-(hydroxymethyl)-3-(1h-indol-3-yl)-19-methyl-15,16,17-trithia-10,12,19-triazapentacyclo[12.3.2.0¹,¹².0³,¹¹.0⁴,⁹]nonadeca-4,6,8-triene-13,18-dione

(1s,2s,3r,11r,14s)-2-hydroxy-14-(hydroxymethyl)-3-(1h-indol-3-yl)-19-methyl-15,16,17-trithia-10,12,19-triazapentacyclo[12.3.2.0¹,¹².0³,¹¹.0⁴,⁹]nonadeca-4,6,8-triene-13,18-dione

C23H20N4O4S3 (512.0647)


   

2-hydroxy-14-(hydroxymethyl)-3-(1h-indol-3-yl)-19-methyl-15,16,17-trithia-10,12,19-triazapentacyclo[12.3.2.0¹,¹².0³,¹¹.0⁴,⁹]nonadeca-4,6,8-triene-13,18-dione

2-hydroxy-14-(hydroxymethyl)-3-(1h-indol-3-yl)-19-methyl-15,16,17-trithia-10,12,19-triazapentacyclo[12.3.2.0¹,¹².0³,¹¹.0⁴,⁹]nonadeca-4,6,8-triene-13,18-dione

C23H20N4O4S3 (512.0647)


   

(5-hydroxy-7-methyl-9,10-dioxo-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}anthracen-2-yl)oxidanesulfonic acid

(5-hydroxy-7-methyl-9,10-dioxo-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}anthracen-2-yl)oxidanesulfonic acid

C21H20O13S (512.0625)


   

(5-hydroxy-7-methyl-9,10-dioxo-4-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}anthracen-2-yl)oxidanesulfonic acid

(5-hydroxy-7-methyl-9,10-dioxo-4-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}anthracen-2-yl)oxidanesulfonic acid

C21H20O13S (512.0625)


   

methyl 2-{3-[3-(3,4-dihydroxyphenyl)-8,10-dihydroxy-6-oxo-2,4-dioxatricyclo[5.4.0.0³,⁵]undeca-1(11),7,9-trien-5-yl]-2,4,6-trihydroxyphenyl}-2-oxoacetate

methyl 2-{3-[3-(3,4-dihydroxyphenyl)-8,10-dihydroxy-6-oxo-2,4-dioxatricyclo[5.4.0.0³,⁵]undeca-1(11),7,9-trien-5-yl]-2,4,6-trihydroxyphenyl}-2-oxoacetate

C24H16O13 (512.0591)


   

methyl 2-{3-[(3r)-3-(3,4-dihydroxyphenyl)-8,10-dihydroxy-6-oxo-2,4-dioxatricyclo[5.4.0.0³,⁵]undeca-1(11),7,9-trien-5-yl]-2,4,6-trihydroxyphenyl}-2-oxoacetate

methyl 2-{3-[(3r)-3-(3,4-dihydroxyphenyl)-8,10-dihydroxy-6-oxo-2,4-dioxatricyclo[5.4.0.0³,⁵]undeca-1(11),7,9-trien-5-yl]-2,4,6-trihydroxyphenyl}-2-oxoacetate

C24H16O13 (512.0591)


   

(1s,2s,3r,11r,14r)-2-hydroxy-14-(hydroxymethyl)-3-(1h-indol-3-yl)-19-methyl-15,16,17-trithia-10,12,19-triazapentacyclo[12.3.2.0¹,¹².0³,¹¹.0⁴,⁹]nonadeca-4,6,8-triene-13,18-dione

(1s,2s,3r,11r,14r)-2-hydroxy-14-(hydroxymethyl)-3-(1h-indol-3-yl)-19-methyl-15,16,17-trithia-10,12,19-triazapentacyclo[12.3.2.0¹,¹².0³,¹¹.0⁴,⁹]nonadeca-4,6,8-triene-13,18-dione

C23H20N4O4S3 (512.0647)


   

7-(3,5-dihydroxyphenoxy)-3-(2,4,6-trihydroxyphenoxy)oxanthrene-1,2,6,8-tetrol

7-(3,5-dihydroxyphenoxy)-3-(2,4,6-trihydroxyphenoxy)oxanthrene-1,2,6,8-tetrol

C24H16O13 (512.0591)


   

5,7-dihydroxy-4-oxo-2-phenyl-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}chromene-8-sulfonic acid

5,7-dihydroxy-4-oxo-2-phenyl-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}chromene-8-sulfonic acid

C21H20O13S (512.0625)


   

5,7-dihydroxy-4-oxo-2-phenyl-3-{[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}chromene-8-sulfonic acid

5,7-dihydroxy-4-oxo-2-phenyl-3-{[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}chromene-8-sulfonic acid

C21H20O13S (512.0625)